MedTrace Logo

Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma

NCT01238159 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2015-03-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of concomitant chemoradiation followed by MIDLE chemotherapy for stage I/II extranodal NK/T cell lymphoma.

Conditions

  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

RADIATION

CCRT+MIDLE chemotherapy

Patients are planned to be treated with CCRT plus MIDLE chemotherapy

Sponsors & Collaborators

  • Asan Medical Center

    collaborator OTHER

  • Yonsei University

    collaborator OTHER

  • Seoul National University

    collaborator OTHER

  • Chonnam National University

    collaborator OTHER

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Won Seog Kim, MD, PhD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01238159 on ClinicalTrials.gov